#COVID VACCINE INFOGRAPHIC SERIES#
Children 6 months through 5 years of age who are unvaccinated may receive a two-dose series of the Moderna bivalent vaccine (6 months through 5 years of age) OR a three-dose series of the Pfizer-BioNTech bivalent vaccine (6 months through 4 years of age).Most unvaccinated individuals may receive a single dose of a bivalent vaccine, rather than multiple doses of the original monovalent mRNA vaccines.However, for immunocompromised individuals 6 months through 4 years of age, eligibility for additional doses will depend on the vaccine previously received. Most individuals with certain kinds of immunocompromise who have received a bivalent COVID-19 vaccine may receive a single additional dose of a bivalent COVID-19 vaccine at least 2 months following a dose of a bivalent COVID-19 vaccine, and additional doses may be administered at the discretion of, and at intervals determined by, their healthcare provider.Individuals 65 years of age and older who have received a single dose of a bivalent vaccine may receive one additional dose at least four months following their initial bivalent dose.The FDA intends to make decisions about future vaccination after receiving recommendations on the fall strain composition at an FDA advisory committee in June. Most individuals who have already received a single dose of the bivalent vaccine are not currently eligible for another dose.Most individuals, depending on age, previously vaccinated with a monovalent COVID-19 vaccine who have not yet received a dose of a bivalent vaccine may receive a single dose of a bivalent vaccine.The monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States. This action includes authorizing the current bivalent vaccines (original and omicron BA.4/BA.5 strains) to be used for all doses administered to individuals 6 months of age and older, including for an additional dose or doses for certain populations.
Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals.
Though there will be immense logistical challenges in ensuring that everyone has timely access to a vaccine, we are one step closer to a post COVID-19 world.Today, the U.S. COVID-19 vaccines have been developed on an accelerated timeline because of the exceptional circumstances, but they nevertheless went through the entire regulatory review and approval process. That’s how vaccination campaigns have helped bring many diseases under control. When enough people are vaccinated, a disease can no longer spread through the population. The mRNA template is then quickly degraded by our normal cellular processes. Once inside cells, the mRNA serves as a template to make the spike protein, and our immune system then learns about it and is ready to fight off the virus. Instead, the vaccine carries mRNA from a key virus gene that makes the spike protein.
In this approach, patients are never exposed to the virus, even in a weakened form. In the case of COVID-19, some of the vaccines use a new technique based around messenger RNA (mRNA). Modern approaches use weakened or inactivated viruses, or even fragments of a virus, but the principle remains the same: safely expose the immune system to a pathogen so immune cells learn to recognize it and can react quickly and effectively the next time it appears. Historically, the earliest way to accomplish this was to get a mild infection that conferred immunity to a stronger disease for example, exposure to cowpox to prevent getting the much more deadly smallpox. The basic principle of vaccination is to prime the immune system so it is better prepared to meet a pathogen. In this infographic, Nature Middle East offers a broad overview of vaccines, how they work, and how the COVID-19 vaccines fit into the picture. For some, however, the news spurred anxiety about whether the vaccines would be safe. The COVID-19 vaccines continue a long history of saving lives and keeping people healthy.Ĭonceptualized by: Sedeer el-Showk Design: Youssef KhalilĪs 2020 drew to a close, news that COVID-19 vaccines were likely to be approved soon brought relief to many.
0 kommentar(er)
